ACAD Company Profile and Key Details

Q: Who are the executives of ACAD?

Dr. Srdjan R. Stankovic M.D., M.S.P.H.PresMr. Austin D. KimExecutive Vice President, Gen. Counsel & Sec.Mr. James K. KiharaVice President, Chief Accounting Officer & Corporation ControllerMr. Bob MischlerSenior Vice President of Strategy & Technology OperationsMr. Mark C. JohnsonVice President of Investor RelationsMs. Julie FisherSenior Vice President of Marketing & Commercial StrategyMr. Mark C. SchneyerExecutive Vice President & Chief Financial OfficerDr. Mary Ellen TurnerSenior Vice President of Pharmacovigilance & Corporation Safety OfficerMr. Rob AcklesSenior Vice President & Chief People OfficerMs. Holly ValdiviezSenior Vice President & Head of SalesMs. Ponni Subbiah M.D., M.P.H.SVice President, Global Head of Medical Affairs & Chief Medical OfficerMr. Brendan P. TeehanExecutive Vice President, Chief Operating Officer & Head of CommercialMr. Stephen R. Davis J.D.Pres, Chief Executive Officer & Director

NASDAQ : ACAD

ACADIA Pharmaceuticals

$23.72

0.36+1.54%

At Close 4:00 PM

62.35

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

ACADIA Pharmaceuticals Inc. (ACAD) stock surged +1.54%, trading at $23.72 on NASDAQ, up from the previous close of $23.36. The stock opened at $23.32, fluctuating between $23.28 and $24.11 in the recent session.

Stock Snapshot

23.36

Prev. Close

4.06B

Market Cap

23.28

Day Low

11.63

P/E Ratio

2.04

EPS (TTM)

-0.14

Cash Flow per Share

23.32

Open

171.24M

Number of Shares

24.105

Day High

99.21%

Free Float in %

2.62

Book Value

1.49M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 25, 2026	23.28	24.11	23.28	23.72	1.49M
Jun 24, 2026	22.67	23.79	22.67	23.36	1.5M
Jun 23, 2026	22.26	22.66	22.01	22.60	1.48M
Jun 22, 2026	21.64	22.46	21.59	22.09	1.9M
Jun 18, 2026	21.73	21.90	21.20	21.62	3.23M
Jun 17, 2026	20.99	21.73	20.92	21.60	1.34M
Jun 16, 2026	21.34	21.47	20.84	20.94	1.24M
Jun 15, 2026	21.10	21.39	21.05	21.27	1.21M
Jun 12, 2026	21.49	21.55	21.05	21.09	753.93K
Jun 11, 2026	21.12	21.68	20.92	21.39	945.09K
Jun 10, 2026	21.79	22.15	21.23	21.25	1.23M
Jun 09, 2026	21.86	22.03	21.47	21.84	1.1M
Jun 08, 2026	21.56	21.79	21.27	21.70	883.77K
Jun 05, 2026	21.71	21.96	21.45	21.56	806.26K
Jun 04, 2026	21.72	21.85	21.48	21.72	1.12M
Jun 03, 2026	20.87	21.44	20.76	21.43	1.24M
Jun 01, 2026	21.40	21.60	20.96	21.52	1.12M
May 29, 2026	21.65	21.96	21.58	21.66	1.74M
May 28, 2026	21.00	21.83	20.89	21.63	1.08M
May 27, 2026	21.48	21.60	21.14	21.19	982.35K

Contact Details

San Diego, CA 92130

United States

https://www.acadia-pharm.com 858 558 2871

About Company

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

Stock Peers

ARGX

36.15+4.24%

argenx SE$888.65 REGN

-3.29-0.53%

Regeneron Pharmaceuticals, Inc.$620.14 UTHR

-6.51-1.18%

United Therapeutics Corporation$543.39 MDGL

4.03+0.79%

Madrigal Pharmaceuticals, Inc.$513.79 VRTX

4.98+1.05%

Vertex Pharmaceuticals Incorporated$480.18 KRYS

12.3+3.54%

Krystal Biotech, Inc.$359.93 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

18.92+6.12%

Praxis Precision Medicines, Inc.$327.86 LGND

11.01+3.86%

Ligand Pharmaceuticals Incorporated$295.92 ALNY

-0.89-0.30%

Alnylam Pharmaceuticals, Inc.$293.17

Company Overview

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) closed at $23.72 USD, gaining $0.36 (1.54%) from the previous close of $23.36. The stock is currently mid-range between its 52-week high and low $19.69 and $28.35. With a market capitalization of about $4.06 billion, ACADIA Pharmaceuticals Inc. is classified as a mid-cap and shows market-like volatility (beta ~0.83). Key stats such as the average daily volume over the past year has been around 1.61 million shares, in line with its 52-week average. Headquartered in San Diego, CA, ACADIA Pharmaceuticals Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Catherine E. Owen Adams, the company employs approximately 653 people and listed since May 27, 2004. ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 3.01%, SMA50 -4.06%, SMA200 4.14%). The stock’s 14-day RSI is 51.08 (neutral), while the ATR of 1.03 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -13.09% below its high and over 83.88% above its low. Average 10-day trading volume of 1.67 million shares is in line with the 3-month average of 1.64 million, indicating normal recent market interest.

Valuation Metrics

ACADIA Pharmaceuticals Inc. trades at a P/E ratio of 10.55, slightly below the S&P 500 average, with a price-to-sales ratio of 3.68 and a price-to-book ratio of 3.21 trading at moderately above to book value. The P/FCF stands at 18.96, also above market averages.

Dividend & Fair Value

ACADIA Pharmaceuticals Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$11.71. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of -10.71% annually over the next five years. The latest quarter delivered EPS of $0.02. The next quarter is forecast at $0.09. Next year's EPS is expected at $372.04. Analyst sentiment is bullish. Analyst rating data shows there are 14 Strong Buy ratings, 15 Buy ratings, 6 Hold ratings, 1 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $17.00. The high target offers 68.63% upside. The low target suggests -28.33% downside. The mean target is $32.14. This offers 35.5% upside. ACADIA Pharmaceuticals Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 06, 2026, missed forecasts by -50.0%. The prior quarter beat by 1067.88%. Over the last six quarters, Apple has recorded several small beats. These include 30.77% in February 26, 2025.

Shareholding & Insider Activity

ACADIA Pharmaceuticals Inc. has 171.24 million shares outstanding. The public float is 127.18 million shares, elevated short interest at 10.89% of float. This equals 11.75 million shares. The short ratio is 6.82 days. Institutional investors hold 102.5% of the float. Insiders own 0.54%. BAKER BROS. ADVISORS LP holds 3.58 million shares, DAVIS STEPHEN has 186.56 thousand shares and Schneyer Mark C. has 66.14 thousand shares. Over the past six months, insider transactions show net selling. They sold 44.91 thousand shares across 13 transactions.

Financial & Profitability Overview

Over the trailing twelve months, ACADIA Pharmaceuticals generated $726.44M in revenue, or $4.43 per share. Gross margin was 93.70%, operating margin -10.10%, and net profit margin -8.44%. Returns are negative, with ROA at -8.18% and ROE at -14.19%.
On valuation metrics, ACADIA Pharmaceuticals trades at a P/E of 10.55, P/S of 3.68 and P/B of 3.21. The current ratio is 3.59 and quick ratio is 3.48. Operationally, the company’s inventory turnover is 2.96 and cash conversion cycle is 124.98 days. Debt-to-equity is 0.04, supported by a cash flow-to-debt ratio of 2.43.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, ACADIA Pharmaceuticals posted revenue of $726.44M, down slightly from $517.24M in the prior quarter. Gross profit was $680.71M (margin 93.70%). Operating income was - $73.38M (margin -10.1%). Net income was- $61.29M (EPS - $0.37).
The company ended the quarter with $438.87M in cash and short-term investments, a total debt of $57.21M, and net debt of - $131.45M. Total assets were $748.96M, with equity of $431.76M. Financials further reflected stability, with operating cash flow of $16.70M, free cash flow of - $23.35M, and capital expenditures of - $40.05M.

Price Forecast & Outlook

Our AI price prediction model suggests that ACADIA Pharmaceuticals Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.98%, with price expected at $23.25 by July 08, 2026, within a range of $22.84 to $23.66 3-Month Outlook: Projected fall of -33.68%, reaching $15.73 by September 22, 2026, with a range of $14.27 to $16.99. 1-Year Outlook: Projected loss of -10.24%, with price at $21.29 by June 24, 2027, within a range of $20.04 to $23.12.

Key Takeaways

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares are flat -1.57% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows ACADIA Pharmaceuticals Inc. trading at a premium to the broader market with a P/E of 10.55. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $28.27, suggesting 19.18% upside. Our AI forecast model points to short-term weakness (-1.98% over two weeks), a medium-term fall (-33.68% over three months), and a longer-term loss (-10.24% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current ACADIA Pharmaceuticals Inc. (ACAD) stock price?

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stock price is $23.72 in the last trading session. During the trading session, ACAD stock reached the peak price of $24.11 while $23.28 was the lowest point it dropped to. The percentage change in ACAD stock occurred in the recent session was 1.54% while the dollar amount for the price change in ACAD stock was $0.36.

ACAD's industry and sector of operation?

The NASDAQ listed ACAD is part of Biotechnology industry that operates in the broader Healthcare sector. ACADIA Pharmaceuticals Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ACAD?

Dr. Srdjan R. Stankovic M.D., M.S.P.H.
Pres
Mr. Austin D. Kim
Executive Vice President, Gen. Counsel & Sec.
Mr. James K. Kihara
Vice President, Chief Accounting Officer & Corporation Controller
Mr. Bob Mischler
Senior Vice President of Strategy & Technology Operations
Mr. Mark C. Johnson
Vice President of Investor Relations
Ms. Julie Fisher
Senior Vice President of Marketing & Commercial Strategy
Mr. Mark C. Schneyer
Executive Vice President & Chief Financial Officer
Dr. Mary Ellen Turner
Senior Vice President of Pharmacovigilance & Corporation Safety Officer
Mr. Rob Ackles
Senior Vice President & Chief People Officer
Ms. Holly Valdiviez
Senior Vice President & Head of Sales
Ms. Ponni Subbiah M.D., M.P.H.
SVice President, Global Head of Medical Affairs & Chief Medical Officer
Mr. Brendan P. Teehan
Executive Vice President, Chief Operating Officer & Head of Commercial
Mr. Stephen R. Davis J.D.
Pres, Chief Executive Officer & Director

How ACAD did perform over past 52-week?

ACAD's closing price is 20.47% higher than its 52-week low of $19.69 where as its distance from 52-week high of $28.35 is -16.33%.

How many employees does ACAD have?

Number of ACAD employees currently stands at 653.

Link for ACAD official website?

Official Website of ACAD is: https://www.acadia-pharm.com

How do I contact ACAD?

ACAD could be contacted at phone 858 558 2871 and can also be accessed through its website. ACAD operates from 12830 El Camino Real, San Diego, CA 92130, United States.

How many shares of ACAD are traded daily?

ACAD stock volume for the day was 1.49M shares. The average number of ACAD shares traded daily for last 3 months was 1.61M.

What is the market cap of ACAD currently?

The market value of ACAD currently stands at $4.06B with its latest stock price at $23.72 and 171.24M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	653
Beta	0.83
Sales or Revenue	$726.44M
5Y Sales Change%	1.508%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ACAD Company Profile and Key Details

ACADIA Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Shareholding & Insider Activity

Valuation Metrics

Key Takeaways

Price Forecast & Outlook